Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

brolucizumab × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Temozolomide 563 Radiotherapy 374 Bevacizumab 230 Magnetic Resonance Spectroscopy 204 Cyclophosphamide 158 Radiosurgery 152 Carboplatin 141 Radiation 116 Etoposide 115 Irinotecan 105 Vincristine 99 Cisplatin 87 Filgrastim 83 Specimen Handling 81 pembrolizumab 79 Nivolumab 75 Lomustine 75 Surgical Procedures, Operative 71 Topotecan 63 Melphalan 53 sargramostim 51 Radiotherapy, Intensity-Modulated 51 Carmustine 51 Isotretinoin 48 Doxorubicin 48 Granulocyte Colony-Stimulating Factor 47 Chemotherapy, Adjuvant 46 Peripheral Blood Stem Cell Transplantation 45 Erlotinib Hydrochloride 44 Blood Specimen Collection 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡